Converging computational and laboratory technologies are helping anti-cancer immune responses hit their target more ...

World Outcomes Of Non-Small Cell Lung Cancer Patients Harbouring Kras G12c And Kras G12d Mutations," published in the March 2025 issue of Lung Cancer by Shahnam et al. KRAS G12D and G12C mutations exh ...

Although activating KRAS mutations occur frequently in cancer, targeting this oncogene has proved difficult. Three groups have now identified pathways that have not been previously linked to KRAS ...

The grant to Dr. Shah provides for the issuance of 191,624 stock options. Additionally, the grants to the two employees provide for the issuance of an aggregate of 21,000 stock options. Each grant ...

The University of Texas MD Anderson Cancer Center is conducting parallel research on a universal vaccine against pancreatic cancer. These studies focus on the KRAS mutation, which is present in 90 ...

Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio Therapeutics" or "Elicio"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies ...

A new analysis of data from the KeyNote-042 trial in previously-untreated NSCLC has shown that the drug is effective regardless of whether a patient’s tumour bears KRAS mutations – which make ...

state of greater than 90% of all KRAS mutations and to provide complete target coverage in tumors. These properties have the potential to translate into best-in-class safety and efficacy.

New study demonstrates how high-affinity B cells 'bank' their best traits instead of rolling the dice and risking deleterious mutations, with implications for better vaccine design. A vaccine's ...

Capturing this mechanism in the lab may lead to more efficient vaccine strategies in the clinic. "Our work shows how high-affinity B cells can bank really advantageous mutations by essentially ...